TP53 and neoplasm: Meanwhile, future research should focus on developing therapies that selectively modulate p53 family isoforms to maximize tumor suppression and minimize off-target effects, exploring the synergistic potential of targeting p53 family pathways alongside immunotherapy and metabolic reprogramming and identifying biomarkers associated with early SCLC progression to enable timely detection and intervention.